Boothbay Fund Management LLC Boosts Stake in Establishment Labs Holdings Inc. (NASDAQ:ESTA)

Boothbay Fund Management LLC boosted its holdings in Establishment Labs Holdings Inc. (NASDAQ:ESTA - Free Report) by 68.8% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 525,248 shares of the company's stock after purchasing an additional 214,119 shares during the quarter. Establishment Labs comprises 0.6% of Boothbay Fund Management LLC's portfolio, making the stock its 17th largest position. Boothbay Fund Management LLC owned approximately 1.88% of Establishment Labs worth $24,198,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Barclays PLC grew its holdings in Establishment Labs by 9,643.3% in the third quarter. Barclays PLC now owns 31,471 shares of the company's stock worth $1,362,000 after purchasing an additional 31,148 shares during the period. Assenagon Asset Management S.A. purchased a new stake in Establishment Labs in the fourth quarter worth about $12,898,000. Raymond James Financial Inc. purchased a new stake in Establishment Labs in the fourth quarter worth about $5,494,000. Swiss National Bank grew its holdings in Establishment Labs by 2.7% in the fourth quarter. Swiss National Bank now owns 38,500 shares of the company's stock worth $1,774,000 after purchasing an additional 1,000 shares during the period. Finally, KLP Kapitalforvaltning AS purchased a new stake in Establishment Labs in the fourth quarter worth about $161,000. Hedge funds and other institutional investors own 72.91% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on ESTA. Needham & Company LLC began coverage on shares of Establishment Labs in a report on Monday, April 14th. They set a "hold" rating on the stock. Stephens reiterated an "overweight" rating and set a $52.00 price target on shares of Establishment Labs in a report on Thursday, March 6th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, Establishment Labs presently has an average rating of "Moderate Buy" and an average price target of $57.40.

Establishment Labs Stock Performance

Establishment Labs stock traded up $0.69 during midday trading on Tuesday, reaching $30.26. 198,175 shares of the company traded hands, compared to its average volume of 459,119. The firm has a market capitalization of $872.88 million, a price-to-earnings ratio of -11.73 and a beta of 0.77. The business has a 50 day moving average of $35.96 and a two-hundred day moving average of $39.14. Establishment Labs Holdings Inc. has a 12 month low of $26.56 and a 12 month high of $60.12. The company has a debt-to-equity ratio of 5.94, a current ratio of 3.62 and a quick ratio of 2.29.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($0.98) earnings per share for the quarter, missing analysts' consensus estimates of ($0.64) by ($0.34). The company had revenue of $44.51 million for the quarter, compared to the consensus estimate of $44.45 million. Establishment Labs had a negative net margin of 46.13% and a negative return on equity of 184.55%. As a group, research analysts predict that Establishment Labs Holdings Inc. will post -2.41 earnings per share for the current year.

Establishment Labs Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.